

HR 8624

Protecting Access to Innovation During COVID–19 Act

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Oct 16, 2020

Current Status: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means

Latest Action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (Oct 16, 2020)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/8624>

Sponsor

Name: Rep. Wenstrup, Brad R. [R-OH-2]

Party: Republican • **State:** OH • **Chamber:** House

Cosponsors (6 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Bishop, Sanford D., Jr. [D-GA-2]	D · GA		Oct 16, 2020
Rep. Harris, Andy [R-MD-1]	R · MD		Oct 30, 2020
Rep. Fitzpatrick, Brian K. [R-PA-1]	R · PA		Nov 12, 2020
Rep. Kelly, Mike [R-PA-16]	R · PA		Nov 12, 2020
Rep. Marchant, Kenny [R-TX-24]	R · TX		Nov 12, 2020
Rep. Hudson, Richard [R-NC-8]	R · NC		Dec 7, 2020

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Oct 16, 2020
Ways and Means Committee	House	Referred To	Oct 16, 2020

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 HR 14	Related bill	Nov 2, 2020: Referred to the Subcommittee on Railroads, Pipelines, and Hazardous Materials.

Protecting Access to Innovation During COVID-19 Act

This bill allows the Centers for Medicare & Medicaid Services (CMS) to extend the duration of pass-through status (i.e., additional payment) for certain drugs and devices under the Medicare prospective payment system for hospital outpatient department services.

Specifically, the CMS may extend the pass-through status of drugs and devices that received such status during the public health emergency relating to COVID-19 (i.e., coronavirus disease 2019) if their cost cannot be accurately calculated due to the effects of COVID-19. The bill's provisions apply to drugs and devices that had pass-through status during any portion of the public health emergency period, including those for which such status has already expired.

Actions Timeline

- **Oct 16, 2020:** Introduced in House
- **Oct 16, 2020:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.